SINGAPORE (Aug 27): As cancer rates rise, particularly in Asia, the fight to contain it becomes all the more urgent, yet treatment drugs are not always available, not for lack of advances in scientific research, either. “High-potential oncology drugs get neglected for reasons [that have] nothing to do with science but more to do with corporate limitations of the healthcare industry,” says Vishal Doshi, CEO of biomedical start-up AUM Biosciences in an interview with The Edge Singapore. AUM Biosciences is looking to change that. “We feel that it is the need of the hour,” says Doshi.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $4.99/month*

The latest reporting and analysis from business and investments to news and views on social issues.

Bonus:

  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply

SUBSCRIBE NOW